NEW YORK (GenomeWeb News) – Cancer genetic testing firm NeoGenomics today said that its revenues for the first quarter bounced 3 percent year over year.

Revenues for the three months ending March 31 totaled $15.7 million, compared to $15.2 million a year ago, as the number of requisitions in the quarter increased to 20,604 from 16,934 a year ago, and the number of tests performed climbed to 32,088 from 26,932.

Net income was down, however, to $3,000, or breakeven on a per-share basis, compared to a profit of $603,000, or $.01 per share, a year ago.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Two researchers have found that behavioral genetic defenses in criminal cases don't tend to affect outcomes, according to Popular Science.

Researchers report that while host genetics influence the oral microbiome, they don't appear to affect cavity-causing microbes, the Economist says.

Pandas' gut microbiomes change as what they eat changes with the seasons, writes Discover's Inkfish blog.

In PLOS this week: comparative genomic study of malaria-linked macaque parasite, search for apple root reference genes, and more.